邮件订阅 RSS

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

成纤维细胞生长因子受体1在非小细胞肺癌中的研究进展

刘磊,  张家齐,  王桂阁,  黄诚,  李力,  梁乃新,  李单青

downloadPDF
文章导航 > 协和医学杂志  > 2019 >  10(6): 666-672
刘磊, 张家齐, 王桂阁, 黄诚, 李力, 梁乃新, 李单青. 成纤维细胞生长因子受体1在非小细胞肺癌中的研究进展[J]. 协和医学杂志, 2019, 10(6): 666-672. doi: 10.3969/j.issn.1674-9081.2019.06.020
引用本文: 刘磊, 张家齐, 王桂阁, 黄诚, 李力, 梁乃新, 李单青. 成纤维细胞生长因子受体1在非小细胞肺癌中的研究进展[J]. 协和医学杂志, 2019, 10(6): 666-672. doi: 10.3969/j.issn.1674-9081.2019.06.020
shu
Lei LIU, Jia-qi ZHANG, Gui-ge WANG, Cheng HUANG, Li LI, Nai-xin LIANG, Shan-qing LI. Fibroblast Growth Factor Receptor 1 in Non-small Cell Lung Cancer[J]. Medical Journal of Peking Union Medical College Hospital, 2019, 10(6): 666-672. doi: 10.3969/j.issn.1674-9081.2019.06.020
Citation: Lei LIU, Jia-qi ZHANG, Gui-ge WANG, Cheng HUANG, Li LI, Nai-xin LIANG, Shan-qing LI. Fibroblast Growth Factor Receptor 1 in Non-small Cell Lung Cancer[J]. Medical Journal of Peking Union Medical College Hospital, 2019, 10(6): 666-672. doi: 10.3969/j.issn.1674-9081.2019.06.020
shu

成纤维细胞生长因子受体1在非小细胞肺癌中的研究进展

doi: 10.3969/j.issn.1674-9081.2019.06.020

  • 中国医学科学院 北京协和医学院 北京协和医院胸外科, 北京 100730

详细信息
    通讯作者:

    李单青 电话:010-69152630, E-mail:lidanqing@pumch.cn

  • 中图分类号: R734.2;R-1

Fibroblast Growth Factor Receptor 1 in Non-small Cell Lung Cancer

  • Department of Thoracic Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China

More Information

    摘要
  • 摘要: 非小细胞肺癌(non-small cell lung cancer, NSCLC)已成为全世界癌症患者死亡的主要原因之一, 其治疗成为目前研究热点。但NSCLC中成纤维细胞生长因子受体(fibroblast growth factor receptor, FGFR)基因突变以及间变性淋巴瘤激酶(anaplastic lymphoma kinase, ALK)融合基因发生率低, 相应靶向药物治疗的总体效果并不理想。FGFR1作为NSCLC中较常见的异常基因, 其异常扩增高表达与多种肿瘤的发生发展相关, 同时发现多种相关的分子靶向药物对肿瘤有抑制作用。本文对FGFR1在NSCLC中的扩增高表达情况、其与NSCLC临床特点之间的关系以及目前相关靶向药物治疗研究进展作一综述。
    Abstract: Non-small cell lung cancer (NSCLC) has become one of the leading causes of death by cancer in the world. Research on the treatment of lung cancer has become a hot spot. The incidence of fibroblast growth factor receptor (FGFR) gene mutation and anaplastic lymphoma kinase gene fusion in NSCLC is low, and the curative effect of corresponding targeted drug treatment is not satisfactory. FGFR1 is a common abnormal gene in non-small cell lung cancer. Recent study gradually found its abnormal amplification in various tumors, and also found that various related molecular-targeting drugs have an inhibitory effect on the corresponding tumor. This paper reviews the expression of FGFR1 in non-small cell lung cancer, its relationship with the clinical characteristics of NSCLC, and current research progress in targeted drug therapy.
    利益冲突  无
    • HTML全文
    • 参考文献(58)
  • [1] Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017[J]. CA Cancer J Clin, 2017, 67:7-30. doi:  10.3322/caac.21387
    [2] Asamura H, Chansky K, Crowley J, et al. The International Association for the Study of Lung Cancer Lung Cancer Staging Project:Proposals for the Revision of the N Descriptors in the Forthcoming 8th Edition of the TNM Classification for Lung Cancer[J]. J Thorac Oncol, 2015, 10:1675-1684. doi:  10.1097/JTO.0000000000000678
    [3] Chansky K, Detterbeck FC, Nicholson AG, et al. The IASLC Lung Cancer Staging Project:External Validation of the Revision of the TNM Stage Groupings in the Eighth Edition of the TNM Classification of Lung Cancer[J]. J Thorac Oncol, 2017, 12:1109-1121. doi:  10.1016/j.jtho.2017.04.011
    [4] Dutt A, Ramos AH, Hammerman PS, et al. Inhibitor-sensitive FGFR1 amplification in human non-small cell lung cancer[J]. PLoS One, 2011, 6:e20351. doi:  10.1371/journal.pone.0020351
    [5] Weiss J, Sos ML, Seidel D, et al. Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer[J]. Sci Transl Med, 2010, 2:62ra93. http://bioinformatics.oxfordjournals.org/cgi/ijlink?linkType=ABST&journalCode=scitransmed&resid=2/62/62ra93
    [6] Malchers F, Dietlein F, Schottle J, et al. Cell-autonomous and non-cell-autonomous mechanisms of transformation by amplified FGFR1 in lung cancer[J]. Cancer Discov, 2014, 4:246-257. doi:  10.1158/2159-8290.CD-13-0323
    [7] Turner NC, Seckl MJ. A therapeutic target for smoking-associated lung cancer[J]. Sci Transl Med, 2010, 2:62ps56. http://www.ncbi.nlm.nih.gov/pubmed/21160076/
    [8] Prié D, Friedlander G. Reciprocal control of 1, 25-dihydroxyvitamin D and FGF23 formation involving the FGF23/Klotho system[J]. Clin J Am Soc Nephrol, 2010, 5:1717-1722. doi:  10.2215/CJN.02680310
    [9] Olsen SK, Ibrahimi OA, Raucci A, et al. Insights into the molecular basis for fibroblast growth factor receptor autoinhibition and ligand-binding promiscuity[J]. Proc Natl Acad Sci U S A, 2004, 101:935-940. doi:  10.1073/pnas.0307287101
    [10] Mohammadi M, Olsen SK, Ibrahimi OA. Structural basis for fibroblast growth factor receptor activation[J]. Cytokine Growth Factor Rev, 2005, 16:107-137. doi:  10.1016/j.cytogfr.2005.01.008
    [11] Marek L, Ware KE, Fritzsche A, et al. Fibroblast growth factor (FGF) and FGF receptor-mediated autocrine signaling in non-small-cell lung cancer cells[J]. Mol Pharmacol, 2009, 75:196-207. doi:  10.1124/mol.108.049544
    [12] Pros E, Lantuejoul S, Sanchez-Verde L, et al. Determining the profiles and parameters for gene amplification testing of growth factor receptors in lung cancer[J]. Int J Cancer, 2013, 133:898-907. doi:  10.1002/ijc.28090
    [13] Kim HR, Kim DJ, Kang DR, et al. Fibroblast growth factor receptor 1 gene amplification is associated with poor survival and cigarette smoking dosage in patients with resected squamous cell lung cancer[J]. J Clin Oncol, 2013, 31:731-737. doi:  10.1200/JCO.2012.43.8622
    [14] Heist RS, Mino-Kenudson M, Sequist LV, et al. FGFR1 amplification in squamous cell carcinoma of the lung[J]. J Thorac Oncol, 2012, 7:1775-1780. doi:  10.1097/JTO.0b013e31826aed28
    [15] Schildhaus HU, Heukamp LC, Merkelbach-bruse S, et al. Definition of a fluorescence in-situ hybridization score iden-tifies high-and low-level FGFR1 amplification types in squa-mous cell lung cancer[J]. Mod Pathol, 2012, 25:1473-1480. doi:  10.1038/modpathol.2012.102
    [16] Rooney C, Geh C, Williams V, et al. Characterization of FGFR1 Locus in sqNSCLC Reveals a Broad and Heterogeneous Amplicon[J]. PLoS One, 2016, 11:e0149628. doi:  10.1371/journal.pone.0149628
    [17] Gadgeel SM, Chen W, Cote ML, et al. Fibroblast growth factor receptor 1 amplification in non-small cell lung cancer by quantitative real-time PCR[J]. PLoS One, 2013, 8:e79820. doi:  10.1371/journal.pone.0079820
    [18] Sasaki H, Shitara M, Yokota K, et al. Increased FGFR1 copy number in lung squamous cell carcinomas[J]. Mol Med Rep, 2012, 5:725-728. http://www.ncbi.nlm.nih.gov/pubmed/22179561
    [19] Ornitz DM, Itoh N. Fibroblast growth factors[J]. Genome Biol, 2001, 2: Reviews3005.
    [20] Stachowiak MK, Maher PA, Stachowiak EK. Integrative nuclear signaling in cell development-a role for FGF receptor-1[J]. DNA Cell Biol, 2007, 26:811-826. doi:  10.1089/dna.2007.0664
    [21] Powell PP, Wang CC, Horinouchi H, et al. Differential expression of fibroblast growth factor receptors 1 to 4 and ligand genes in late fetal and early postnatal rat lung[J]. Am J Respir Cell Mol Biol, 1998, 19:563-572. doi:  10.1165/ajrcmb.19.4.2994
    [22] Hyder SM, Murthy L, Stancel GM. Progestin regulation of vascular endothelial growth factor in human breast cancer cells[J]. Cancer Res, 1998, 58:392-395.
    [23] Schafer MH, Lingohr P, Strasser A, et al. Fibroblast growth factor receptor 1 gene amplification in gastric adenocar-cinoma[J]. Hum Pathol, 2015, 46:1488-1495. doi:  10.1016/j.humpath.2015.06.007
    [24] Kwak Y, Nam SK, Seo AN, et al. Fibroblast Growth Factor Receptor 1 Gene Copy Number and mRNA Expression in Primary Colorectal Cancer and Its Clinicopathologic Correlation[J]. Pathobiology, 2015, 82:76-83. doi:  10.1159/000398807
    [25] Fernanda Amary M, Ye H, Berisha F, et al. Fibroblastic growth factor receptor 1 amplification in osteosarcoma is associated with poor response to neo-adjuvant chemotherapy[J]. Cancer Med, 2014, 3:980-987. doi:  10.1002/cam4.268
    [26] Behrens C, Lin HY, Lee JJ, et al. Immunohistochemical expression of basic fibroblast growth factor and fibroblast growth factor receptors 1 and 2 in the pathogenesis of lung cancer[J]. Clin Cancer Res, 2008, 14:6014-6022. doi:  10.1158/1078-0432.CCR-08-0167
    [27] Beroukhim R, Mermel CH, Porter D, et al. The landscape of somatic copy-number alteration across human cancers[J]. Nature, 2010, 463:899-905. doi:  10.1038/nature08822
    [28] Soundararajan P, Fawcett JP, Rafuse VF. Guidance of postural motoneurons requires MAPK/ERK signaling downstream of fibroblast growth factor receptor 1[J]. J Neurosci, 2010, 30:6595-6606. doi:  10.1523/JNEUROSCI.4932-09.2010
    [29] Kuslak SL, Marker PC. Fibroblast growth factor receptor signaling through MEK-ERK is required for prostate bud induction[J]. Differentiation, 2007, 75:638-651. doi:  10.1111/j.1432-0436.2006.00161.x
    [30] Williamson AJ, Dibling BC, Boyne JR, et al. Basic fibroblast growth factor-induced cell death is effected through sustained activation of p38MAPK and up-regulation of the death receptor p75NTR[J]. J Biol Chem, 2004, 279:47912-47928. doi:  10.1074/jbc.M409035200
    [31] Kranenburg AR, De Boer WI, Van Krieken JH, et al. Enhanced expression of fibroblast growth factors and receptor FGFR-1 during vascular remodeling in chronic obstructive pulmonary disease[J]. Am J Respir Cell Mol Biol, 2002, 27:517-525. doi:  10.1165/rcmb.4474
    [32] Kranenburg AR, Willems-widyastuti A, Mooi WJ, et al. Chronic obstructive pulmonary disease is associated with enhanced bronchial expression of FGF-1, FGF-2, and FGFR-1[J]. J Pathol, 2005, 206:28-38. doi:  10.1002/path.1748
    [33] Schwartz AG, Ruckdeschel JC. Familial lung cancer:genetic susceptibility and relationship to chronic obstructive pulmonary disease[J]. Am J Respir Crit Care Med, 2006, 173:16-22. doi:  10.1164/rccm.200502-235PP
    [34] Ruotsalainen T, Joensuu H, Mattson K, et al. High pretreatment serum concentration of basic fibroblast growth factor is a predictor of poor prognosis in small cell lung cancer[J]. Cancer Epidemiol Biomarkers Prev, 2002, 11:1492-1495.
    [35] Joensuu H, Anttonen A, Eriksson M, et al. Soluble syndecan-1 and serum basic fibroblast growth factor are new prognostic factors in lung cancer[J]. Cancer Res, 2002, 62:5210-5217. http://www.ncbi.nlm.nih.gov/pubmed/12234986/
    [36] Cihoric N, Savic S, Schneider S, et al. Prognostic role of FGFR1 amplification in early-stage non-small cell lung cancer[J]. Br J Cancer, 2014, 110:2914-2922. doi:  10.1038/bjc.2014.229
    [37] Cancer Genome Atlas Research Network.Comprehensive genomic characterization of squamous cell lung cancers[J]. Nature, 2012, 489:519-525. doi:  10.1038/nature11404
    [38] Preusser M, Berghoff AS, Berger W, et al. High rate of FGFR1 amplifications in brain metastases of squamous and non-squamous lung cancer[J]. Lung Cancer, 2014, 83:83-89. doi:  10.1016/j.lungcan.2013.10.004
    [39] Kohler LH, Mireskandari M, Knosel T, et al. FGFR1 expression and gene copy numbers in human lung cancer[J]. Virchows Arch, 2012, 461:49-57. doi:  10.1007/s00428-012-1250-y
    [40] Seo AN, Jin Y, Lee HJ, et al. FGFR1 amplification is associated with poor prognosis and smoking in non-small-cell lung cancer[J]. Virchows Arch, 2014, 465:547-558. doi:  10.1007/s00428-014-1634-2
    [41] Zhang J, Zhang L, Su X, et al. Translating the therapeutic potential of AZD4547 in FGFR1-amplified non-small cell lung cancer through the use of patient-derived tumor xenograft models[J]. Clin Cancer Res, 2012, 18:6658-6667. doi:  10.1158/1078-0432.CCR-12-2694
    [42] Wang Y, Gao W, Xu J, et al. The Role of FGFR1 Gene Amplification as a Poor Prognostic Factor in Squamous Cell Lung Cancer:A Meta-Analysis of Published Data[J]. Bio Med Res Int, 2015, 2015:763080.
    [43] Zhang L, Yu H, Badzio A, et al. Fibroblast Growth Factor Receptor 1 and Related Ligands in Small-Cell Lung Cancer[J]. J Thorac Oncol, 2015, 10:1083-1890. doi:  10.1097/JTO.0000000000000562
    [44] Xie FJ, Lu HY, Zheng QQ, et al. The clinical pathological characteristics and prognosis of FGFR1 gene amplification in non-small-cell lung cancer:a meta-analysis[J]. Onco Targets Ther, 2016, 9:171-181. http://search.ebscohost.com/login.aspx?direct=true&db=aph&AN=112980396&site=ehost-live
    [45] Hibi M, Kaneda H, Tanizaki J, et al. FGFR gene alterations in lung squamous cell carcinoma are potential targets for the multikinase inhibitor nintedanib[J]. Cancer Sci, 2016, 107:1667-1676. doi:  10.1111/cas.13071
    [46] Terai H, Soejima K, Yasuda H, et al. Activation of the FGF2-FGFR1 autocrine pathway:a novel mechanism of acquired resistance to gefitinib in NSCLC[J]. Mol Cancer Res, 2013, 11:759-767. doi:  10.1158/1541-7786.MCR-12-0652
    [47] Azuma K, Kawahara A, Sonoda K, et al. FGFR1 activation is an escape mechanism in human lung cancer cells resistant to afatinib, a pan-EGFR family kinase inhibitor[J]. Oncotarget, 2014, 5:5908-5919. doi:  10.18632/oncotarget.1866
    [48] Skaper SD, Kee WJ, Facci L, et al. The FGFR1 inhibitor PD 173074 selectively and potently antagonizes FGF-2 neurotrophic and neurotropic effects[J]. J Neurochem, 2000, 75:1520-1527.
    [49] Trudel S, Ely S, Farooqi Y, et al. Inhibition of fibroblast growth factor receptor 3 induces differentiation and apoptosis in t(4;14) myeloma[J]. Blood, 2004, 103:3521-3528. doi:  10.1182/blood-2003-10-3650
    [50] Goke A, Goke R, Ofner A, et al. The FGFR Inhibitor NVP-BGJ398 Induces NSCLC Cell Death by Activating Caspase-dependent Pathways as well as Caspase-independent Apoptosis[J]. Anticancer Res, 2015, 35:5873-5879.
    [51] Nogova L, Sequist LV, Perez Garcia JM, et al. Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors:Results of a Global Phase Ⅰ, Dose-Escalation and Dose-Expansion Study[J]. J Clin Oncol, 2017, 35:157-165.
    [52] Gavine PR, Mooney L, Kilgour E, et al. AZD4547:an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family[J]. Cancer Res, 2012, 72:2045-2056. doi:  10.1158/0008-5472.CAN-11-3034
    [53] Ren M, Hong M, Liu G, et al. Novel FGFR inhibitor ponatinib suppresses the growth of non-small cell lung cancer cells overexpressing FGFR1[J]. Oncol Rep, 2013, 29:2181-2190. doi:  10.3892/or.2013.2386
    [54] Wynes MW, Hinz TK, Gao D, et al. FGFR1 mRNA and protein expression, not gene copy number, predict FGFR TKI sensitivity across all lung cancer histologies[J]. Clin Cancer Res, 2014, 20:3299-3309. doi:  10.1158/1078-0432.CCR-13-3060
    [55] Lim SH, Sun JM, Choi YL, et al. Efficacy and safety of dovitinib in pretreated patients with advanced squamous non-small cell lung cancer with FGFR1 amplification:A single-arm, phase 2 study[J]. Cancer, 2016, 122:3024-3031. doi:  10.1002/cncr.30135
    [56] Semrad TJ, Kim EJ, Tanaka MS, et al. Phase Ⅱ Study of Dovitinib in Patients Progressing on Anti-Vascular Endo-thelial Growth Factor Therapy[J]. Cancer Treat Res Commun, 2017, 10:21-26. doi:  10.1016/j.ctarc.2016.12.002
    [57] Reck M, Kaiser R, Mellemgaard A, et al. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1):a phase 3, double-blind, randomised controlled trial[J]. Lancet Oncol, 2014, 15:143-155. doi:  10.1016/S1470-2045(13)70586-2
    [58] Hanna NH, Kaiser R, Sullivan RN, et al. Nintedanib plus pemetrexed versus placebo plus pemetrexed in patients with relapsed or refractory, advanced non-small cell lung cancer (LUME-Lung 2):A randomized, double-blind, phase Ⅲ trial[J]. Lung Cancer, 2016, 102:65-73. doi:  10.1016/j.lungcan.2016.10.011
    • 相关文章
    • 施引文献
  • 资源附件(0)
  • 加载中
WeChat 点击查看大图
计量
  • 文章访问数:  500
  • HTML全文浏览量:  30
  • PDF下载量:  139
  • 被引次数: 0
出版历程
  • 收稿日期:  2017-10-13
  • 刊出日期:  2019-11-30

目录

    /

    返回文章
    返回
    友情链接: 国家卫生健康委员会 北京协和医院 中国医学科学院 学术不端检测系统 国际知识资源总库 中国知网 术语在线 中国全科医学
    地址：北京市东城区帅府园1号 北京协和医院老楼7号楼
    3层302室 《协和医学杂志》编辑部
    电话：010-69154261/4262
    E - mail：medj@pumch.cn
    mjpumch@126.com
    期刊网站版权所有：《协和医学杂志》编辑部
    京ICP备 11002662

    本系统由 北京仁和汇智信息技术有限公司 开发    百度统计

    x 关闭 永久关闭

    【温馨提醒】近日，《协和医学杂志》编辑部接到作者反映，有多名不法人员冒充期刊编辑发送见刊通知，鼓动作者添加微信，从而骗取版面费的行为。特提醒您，本刊与作者联系的方式均为邮件通知或电话，稿件进度通知邮箱为：mjpumch@126.com，编辑部电话为：010-69154261，请提高警惕，谨防上当受骗！如有任何疑问，请致电编辑部核实。谢谢！